Ischemic heart disease Board decisions

The Board remands the claims for further development, including new examinations and medical opinions to clarify diagnoses and establish a nexus between the claimed conditions and service-connected disabilities.

The appeal for service connection for diverticulitis and an effective date prior to August 10, 2022 for CAD disability was dismissed due to a concurrent election of review. An initial evaluation in excess of 30 percent for IBS was denied, but an initial evaluation of 60 percent, but no higher, for the period beginning May 22, 2024, but no earlier, for CAD disability was granted.

The Board denied an effective date prior to August 10, 2022 for the award of service connection for valvular heart disease with cardiomyopathy and atrial fibrillation, sleep apnea, hypertension, erectile dysfunction, and male testis hypogonadism.

The Board remands the claims for service connection for an acquired psychiatric disorder, a stomach disorder, HTN, and a heart condition due to the need for additional evidence.

The Board denied the Veteran's claim for service connection for a heart condition, as there is no evidence of a current diagnosis and the evidence does not support a causal relationship between any in-service incident and a current disability.

The Board remands the claims for service connection for coronary artery disease and obstructive sleep apnea due to a need for an adequate medical opinion considering all conceded exposures.

The Board granted service connection for heart conditions, including aortic insufficiency and trace mitral regurgitation aortic root dilation and arteriosclerotic heart disease (CAD), as well as hypertension, as secondary to the Veteran's service-connected PTSD.

The Board granted service connection for epistaxis and obstructive sleep apnea, but denied an initial compensable rating for bilateral hearing loss. The anxiety disorder was granted a 100 percent rating.

The Board remands the claims for service connection for diabetes mellitus type II, hypertension, ischemic heart disease, and a lung condition due to a pre-decisional duty to assist error regarding SSA records.

The Board remands the claims for service connection for hypertension and arteriosclerotic heart disease (coronary artery disease) to verify the Veteran's exposure to contaminants at McGuire Air Force Base.

The Board granted service connection for coronary artery disease on a presumptive basis due to the Veteran's service in Vietnam. The appeal of entitlement to service connection for a respiratory disorder, including COPD and emphysema, was remanded.

The Board denied the veteran's claims for earlier effective dates and higher ratings for various service-connected conditions, except for a few granted evaluations.

The Board granted service connection for diabetes mellitus, type II, coronary artery disease (CAD), and bilateral upper extremity peripheral neuropathy.

The appeal concerning entitlement to service connection for a heart disability was withdrawn by the Veteran.

The Board remands the matter for further development to obtain an addendum opinion addressing the Veteran's heart conditions and their potential relationship to his military service, medications prescribed for his service-connected disabilities, and toxic exposure.

The Board remands the claim for a heart disability to obtain further medical evidence, as the previous VA opinion was insufficient.

The Board remands the appeal for further development, including obtaining private treatment records and a new medical opinion addressing the Veteran's claims.

The Board denied the veteran's claims for service connection for hypertension and a heart disability, finding no evidence of chronic in-service symptoms or that these conditions were related to his military service.

The Board denied the Veteran's request for an earlier effective date for service connection of myocardial infarction with bradycardia and coronary artery bypass graft (cardiac disability) and tinnitus, as no prior claim was received before July 22, 2024.

The Board granted an initial rating of 30 percent, but not higher, prior to November 14, 2021 for stable angina and valvular heart disease associated with hypertension. The claim for a rating in excess of 30 percent since that date was denied.